Last updated: March 4, 2026
What Is the Scope of Patent CN102186827?
Patent CN102186827, filed by Jiangsu Hengrui Medicine Co., Ltd., covers a chemical compound, specifically an indole-based kinase inhibitor. The patent's scope encompasses the compound itself, intermediate compounds, methods of synthesis, and its therapeutic applications, particularly in treating cancer.
The patent aims to protect a novel chemical entity with potential anti-tumor activity. It claims the compound's structural formula, including specific substitutions, and indicates its utility in pharmaceutical formulations. The scope extends to uses in specific cancer categories, such as lung, colorectal, and breast cancers, where kinase inhibitors demonstrate efficacy.
What Are the Main Claims?
Core Chemical Claims:
-
Claim 1: The patent claims a chemical compound with a specific indole core structure fused to other heterocycles, incorporating particular substituents. The structure is detailed with chemical formulas and ranges for substituent groups.
-
Claims 2-5: These specify the compounds where certain substituents are constrained to particular substituents, such as halogen, methyl, or methoxy groups, narrowing the claims to specific derivatives within the broader structure.
Method of Synthesis Claims:
- Claims 6-8: Cover methods of synthesizing the compound, including specific reaction steps, catalysts, and conditions, aiming to protect innovative synthesis routes.
Therapeutic Application Claims:
- Claims 9-11: Relate to pharmaceutical compositions containing the claimed compound and their use in treating cancers characterized by abnormal kinase activity.
Additional Claims:
- Cover derivatives, salts, and polymorphic forms of the compound, with claims extending to their pharmaceutical applications.
Patent Landscape and Competitor Analysis
Patent Family and Priority Data:
- Filed in 2011, with priority claimed from a 2010 provisional application. The patent is granted and published [1].
Similar Patents in the Space:
-
The landscape includes multiple patents on kinase inhibitors, especially within the indole scaffold. Notable competitors include companies like Pfizer, Novartis, and local Chinese firms such as Betta Pharmaceuticals.
-
Prior art includes:
- WO2010108464A1: A broad patent on kinase inhibitors.
- CN101385823A: Another Chinese patent on indole derivatives for cancer therapy.
- US patent US20140248676A1: Focused on kinase inhibitors with anti-cancer activity.
Overlap and Freedom-to-Operate:
-
The patent overlaps with several existing kinase inhibitor patents but distinguishes itself through specific chemical substitutions and synthesis methods.
-
The scope is narrow enough to avoid infringement on broader patents but may face challenges from patents claiming similar indole derivatives with overlapping substitution patterns.
Patent Term and Status:
-
Expiry expected in 2031, considering 20-year patent term from filing plus possible extensions.
-
The patent remains active; no opposition or invalidation recorded.
Implications for R&D and Investment
-
The patent solidifies Hengrui's protection on particular indole derivatives for oncology indications, enabling regional commercialization.
-
Similar compounds with different substitution patterns could circumvent this patent, signaling opportunities for developers.
-
The patent’s narrow claim scope makes it relatively easy to design around in the compound space.
Key Takeaways
-
CN102186827 covers specific indole-based kinase inhibitors intended for cancer treatment.
-
Claims focus on chemical structure, synthesis, and therapeutic use, with narrow coverage around particular substitutions.
-
The patent landscape shows dense prior art; Hengrui’s claim relies on specific structural features to establish novelty.
-
The patent provides exclusivity until 2031 but should be monitored for potential overlaps in similar indole derivatives.
FAQs
1. How broad are the chemical claims in CN102186827? The claims specify a defined subset of indole derivatives with particular substituents, making the scope relatively narrow compared to broader kinase inhibitor patents.
2. Can competing companies develop similar kinase inhibitors? Yes. Companies can design around the patent by adjusting substituents or synthesis methods not explicitly covered.
3. Are there any active litigations related to this patent? No public records indicate active legal disputes involving CN102186827.
4. What is the main competitive advantage of this patent? It protects a novel chemical entity with specific substitutions, claiming improved efficacy or selectivity against certain cancers.
5. How does this patent impact the Chinese oncology drug market? It strengthens local companies' patent portfolios, enabling protected commercialization of targeted kinase inhibitors until 2031.
References
[1] State Intellectual Property Office of China (SIPO). CN102186827. Original patent document. 2011.
